189 related articles for article (PubMed ID: 37929016)
21. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,
Chu Y; Lee S; Shah T; Yin C; Barth M; Miles RR; Ayello J; Morris E; Harrison L; Van de Ven C; Galardy P; Goldman SC; Lim MS; Hermiston M; McAllister-Lucas LM; Giulino-Roth L; Perkins SL; Cairo MS
Oncoimmunology; 2019; 8(1):e1512455. PubMed ID: 30546948
[TBL] [Abstract][Full Text] [Related]
22. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
23. Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Aalipour A; Advani RH
Ther Adv Hematol; 2014 Aug; 5(4):121-33. PubMed ID: 25360238
[TBL] [Abstract][Full Text] [Related]
24. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
25. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
26. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
Das D; Wang J; Hong J
Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
[TBL] [Abstract][Full Text] [Related]
27. Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Teng Y; Lu X; Xiao M; Li Z; Zou Y; Ren S; Cheng Y; Luo G; Xiang H
Eur J Med Chem; 2020 Aug; 199():112339. PubMed ID: 32402933
[TBL] [Abstract][Full Text] [Related]
28. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
Steffanoni S; Batchelor TT
Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
[TBL] [Abstract][Full Text] [Related]
29. Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.
Kueffer LE; Joseph RE; Andreotti AH
Front Cell Dev Biol; 2021; 9():655489. PubMed ID: 34249912
[TBL] [Abstract][Full Text] [Related]
30. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton's Tyrosine Kinase via Molecular Dynamics Simulations.
Yu X; Qiu S; Sun D; Guo P; Li Q
Molecules; 2022 Nov; 27(21):. PubMed ID: 36364276
[TBL] [Abstract][Full Text] [Related]
32. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
[TBL] [Abstract][Full Text] [Related]
34. Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice.
Rip J; de Bruijn MJW; Neys SFH; Singh SP; Willar J; van Hulst JAC; Hendriks RW; Corneth OBJ
Eur J Immunol; 2021 Sep; 51(9):2251-2265. PubMed ID: 34323286
[TBL] [Abstract][Full Text] [Related]
35. The role of Bruton's tyrosine kinase in the immune system and disease.
McDonald C; Xanthopoulos C; Kostareli E
Immunology; 2021 Dec; 164(4):722-736. PubMed ID: 34534359
[TBL] [Abstract][Full Text] [Related]
36. Update on Novel Therapeutics for Primary CNS Lymphoma.
Schaff LR; Grommes C
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771535
[TBL] [Abstract][Full Text] [Related]
37. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
38. Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
Wang X; Kokabee L; Kokabee M; Conklin DS
Front Cell Dev Biol; 2021; 9():668996. PubMed ID: 34307353
[TBL] [Abstract][Full Text] [Related]
39. Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors.
Sousa BB; de Almeida CR; Barahona AF; Lopes R; Martins-Logrado A; Cavaco M; Neves V; Carvalho LAR; Labão-Almeida C; Coelho AR; Leal Bento M; Lopes RMRM; Oliveira BL; Castanho MARB; Neumeister P; Deutsch A; Vladimer GI; Krall N; João C; Corzana F; Seixas JD; Fior R; Bernardes GJL
ACS Pharmacol Transl Sci; 2022 Nov; 5(11):1156-1168. PubMed ID: 36407952
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex.
Vassilev A; Ozer Z; Navara C; Mahajan S; Uckun FM
J Biol Chem; 1999 Jan; 274(3):1646-56. PubMed ID: 9880544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]